40 results about "Serum amyloid P" patented technology

Compositions and methods are provided for the treatment of fibrosis related disorders utilizing the ratio of the concentration of serum amyloid P(SAP) to C-reactive protein (CRP) in a patient. The methods may further comprise determining the R131 / H131 polymorphism of FcγRIIA. Diagnostic methods are also provided.

The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway disease and diseases associated with excessive Th2 pathology. The present invention relates to the surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic affect in the treatment of hypersensitive disorders.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.

The present invention relates to the compound (2R,2′R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate) of formula (I), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

The present invention addresses the problem of providing a reagent kit, measurement kit, and measurement method for immunologically measuring serum amyloid A with high accuracy and high sensitivity, without using an alcohol designated as a hazardous material in the fire protection code. The present invention provides a reagent kit that is for measuring serum amyloid A and that contains: first particles labelled and modified with a first binding substance capable of specifically binding to serum amyloid A; and at least one nonionic surfactant having a molecular weight of 1000 or less.

Functionalized pentraxin-2 (PTX-2) protomers and functionalized PTX-2 pentamers, methods for preparing functionalized PTX-2 protomers and functionalized PTX-2 pentamers, pharmaceutical compositions including functionalized PTX-2 pentamers, and methods for using the same are described herein.

The invention discloses application of serum amyloid A2 in preparation of a kit for detecting lung cancer, and belongs to the field of biotechnology and medicine. The invention particularly discloses the application of serum amyloid protein A2 as a molecular marker in preparation of a kit or a reagent for detecting lung cancer. The serum amyloid protein A2 as the molecular marker is used for early screening and clinical staging of lung cancer. Through test verification, the invention reveals that the high expression of the SAA2 gene is closely associated with the clinical staging of the lung cancer for the first time, discovers that the SAA2 can be used as a marker for detecting tissues and plasma samples of NSCLC patients, and develops a rapid detection reagent or kit for clinical early screening and clinical staging of the lung cancer, thereby providing a new means for diagnosis of the lung cancer.

The present invention is directed to diagnosing, determining, and / or monitoring type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by detecting levels and modulations of Serum amyloid A protein (SAA), SAA variants and / or the phenotypic ratio of SAA. The present invention is also directed to methods for identifying and evaluating therapeutic treatments for type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by monitoring SAA, SAA variants, and / or the phenotypic ration of SAA.

RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.

The present application discloses a test strip for joint detection of C-reactive protein and serum amyloid A, a kit and a preparation method for the test strip. The test strip comprises a bottom plate, a sample pad, a binding pad, a reaction pad and a water-absorbing pad; the binding pad is coated with fluorescent microspheres jointly labeled with CRP antibody and CRP broadened rabbit anti-antibody, SAA antibody and SAA broadened chicken anti-antibody joint label Fluorescent microspheres; CRP detection line, SAA detection line, CRP widening line and SAA widening line are formed on the reaction pad. The test strip and the test kit containing the test strip of this application can simultaneously quantitatively detect the content of CRP and SAA in the sample, with high sensitivity, good specificity, fast detection speed, and a very wide linear range. The linear range of CRP is 0.5-600mg / L, the linear range of SAA is 3-800mg / L, which reduces the repeated dilution of samples in clinical practice and improves the efficiency of clinical diagnosis.

The invention discloses a kit for measuring serum amyloid A content by scattering turbidimetry. The composition of the kit is simple, adding alfalfa saponin can combine with cholesterol to reduce total cholesterol in serum, and can effectively eliminate the interference of cholesterol. The kit is carried out by nephelometry, and the linear range, correlation and sensitivity of the detection are higher than the existing kits, which significantly improves the sensitivity of serum amyloid A detection and solves the problem of existing serum amyloid A detection reagents. Box detection sensitivity, low precision, and narrow linear range.

The invention discloses a hybridoma cell strain 4D4 having the preservation number of CCTCC NO:C2019121; the hybridoma cell strain 4D4 can secrete a monoclonal antibody SAA-McAb1 which can specifically recognize a human serum amyloid A. At the same time, the invention discloses an application of the monoclonal antibody SAA-McAb1 in detection of the human serum amyloid A, and a human serum amyloidA immunoassay kit prepared by the monoclonal antibody SAA-McAb1.

The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

The invention discloses a human serum amyloid A1 and a preparation method and an application thereof. The invention further discloses a polymer of the human serum amyloid A1 and a polypeptide fragment of the human serum amyloid A1. The human serum amyloid A1, the polymer and the polypeptide fragment disclosed by the invention have the capabilities of inhibiting the expression of inflammatory cytokines, and can be used for inhibiting inflammations and treatment inflammation-relevant diseases.

The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the serum amyloid P component (APCS) gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of an APCS gene and to treat subjects having an APCS-associated disease, e.g., amyloidosis, Alzheimer's disease or coronary atherosclerotic heart disease.